In patients with acute exacerbations of chronic obstructive pulmonary disease (COPD), are anticholinergic agents more effective than placebo or β 2 -agonists?
S t u d y s e l e c t i o n
Studies were selected if they were randomized controlled trials (RCTs) comparing anticholinergic agents (ipratropium or oxitropium bromide, given by inhalation by nebulizer or metered-dose inhaler) with an appropriate control (e.g., placebo, other bronchodilating agents, or combination therapies) and assessed adults with a diagnosis of COPD having symptoms of acute exacerbation of COPD. Studies of patients with acute asthma or those receiving ventilation were excluded.
D a t a e x t r a c t i o n
Data were extracted on study quality and methods, participants, interventions, and outcomes (e.g., lung function measurements, arterial blood gas measurements, and symptom scores).
M a i n r e s u l t s 9 RCTs were included. 4 studies compared ipratropium with an inhaled β 2 -agonist, and 5 studies compared ipratropium plus a shortacting β 2 -agonist with a β 2 -agonist alone. The most common outcome reported was FEV 1 . Four studies that compared ipratropium bromide with a β 2 -agonist showed no difference between groups for change in FEV 1 at 90 minutes (weighted mean difference [WMD] 0 L, 95% CI −0.19 to 0.19).
5 studies that compared ipratropium plus a β 2 -agonist with a β 2 -agonist alone also showed no difference between groups for change in FEV 1 at 90 minutes (WMD 0.02 L, CI −0.08 to 0.12) and at 24 hours (WMD −0.05 L, CI −0.14 to 0.05). 2 studies that compared ipratropium with a β 2 -agonist showed no difference between groups for hypoxia (PaO 2 ), either in the short-or long-term.
C o n c l u s i o n
In patients with acute exacerbations of chronic obstructive pulmonary disease, ipratropium alone or combined with a shortacting β 2 -agonist does not increase the degree of bronchodilation more than a short-acting β 2 -agonist used alone. 
C o m m e n t a r y
Current guidelines recommend that an anticholinergic agent be combined with a β 2 -adrenergic agonist when inhaled bronchodilator therapy is prescribed for patients with severe or exacerbated COPD. Short-acting anticholinergics and short-acting β 2 -agonists produce similar bronchodilation in patients with stable COPD (1). Combined therapy produces larger FEV 1 increases than does either agent alone, but the additive effect is modest and the clinical benefit remains uncertain (1) . The meta-analysis by McCrory and Brown shows that anticholinergics and short-acting β 2 -agonists are similar also when given alone to patients hospitalized for COPD exacerbations. However, combined therapy seems to provide no additive bronchodilation during exacerbation, either short-(90 min) or longer-term (24 h).
Several reasons are possible for this seeming disparity, although none are readily apparent. Chance can never be fully excluded. Although several hundred patients are included in the meta-analysis, there is a small possibility that FEV 1 differences as large as 100 mL might not have been detected, and changes of this magnitude during exacerbation seem to be clinically meaningful (2) .
None of the trials included in the meta-analysis attempted to evaluate clinical outcomes. McCrory and Brown suggest the need for a very large trial to better evaluate patient-oriented endpoints, but it is doubtful that support will ever be found for such a large, expensive project. Hence, treatment recommendations will continue to be made from the available evidence, which provides little justification for combining an anticholinergic with a β 2 -agonist in the treatment of COPD exacerbations. As monotherapy, the 2 drug classes seem to be equally effective, and because both have excellent safety profiles, individual patient preference or cost should dictate the choice.
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